Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

Schernthaner, Guntram; Lotan, Chaim; Baltadzhieva-Trendafilova, Elina; Ceponis, Jonas; Clodi, Martin; Ducena, Kristine; Goncalvesova, Eva; Guja, Cristian; Honka, Marek; Janež, Andrej; Lalić, Nebojša; Lehmann, Roger; Nyolczas, Noémi; Pauklin, Priit; Rynkiewicz, Andrzej; Sergienko, Igor; Duvnjak, Lea Smirčić

doi:10.1186/s12933-018-0788-7

Citations

Citation copied

Schernthaner, G., Lotan, C., Baltadzhieva-Trendafilova, E., Ceponis, J., Clodi, M., Ducena, K., Goncalvesova, E., Guja, C., Honka, M., Janež, A., Lalić, N., Lehmann, R., Nyolczas, N., Pauklin, P., Rynkiewicz, A., Sergienko, I., & Duvnjak, L. S. (2018). Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier? Cardiovascular Diabetology, 17, 145. https://doi.org/10.1186/s12933-018-0788-7

Abstract

Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology